- Advertisement -
Dr. Reddy’s Laboratories Ltd. reported today that it has propelled Bivalirudin for Injection, 250 mg/vial, a restorative identical bland rendition of Angiomax (Bivalirudin) for Injection, affirmed by the U.S.
Sustenance and Drug Administration (USFDA).
The Angiomax brand and bland had U.S. offers of around $198 million MAT for the latest twelve months finishing in March 2017 as per IMS Health.
Dr. Reddy’s Bivalirudin Injection, 250 mg/vial, are accessible in bundles of 10 single-measurements vials. Angiomax is an enrolled trademark of The Medicines Company.